Literature DB >> 15339673

Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.

Ada Maria Florena1, Claudio Tripodo, Emilio Iannitto, Rossana Porcasi, Sabrina Ingrao, Vito Franco.   

Abstract

BACKGROUND AND OBJECTIVES: Essential thrombocythemia (ET) is a Philadelphia chromosome-negative chronic myeloproliferative disorder (CMPD) whose diagnosis, according to the Polycythemia Vera Study Group (PVSG) criteria, does not include histopathological data. The new WHO classification of CMPD has supplied new diagnostic guidelines which highlight the value of histopathology and facilitate a more precise differentiation of ET from reactive conditions and other CMPDs. DESIGN AND METHODS: Bone marrow biopsies from 142 adult patients diagnosed with ET according to PVSG criteria were evaluated using the new WHO classification. Megakaryocyte morphology and arrangement, amount of fibrosis and a clustering index were studied along with determination of microvessel density (MVD), amount of CD34+ cells and percentage of MIB-1+ cells and megakaryocytes. The last value, indicated as megakaryocyte proliferation index (MPI), was determined and expressed as a percentage of the counted cells.
RESULTS: According to WHO criteria the 142 biopsies were classified as follows: ET (21%); Idiopathic myelofibrosis (IMF) grade 0 (30%); IMF-1 (34%); IMF-2 (10%) ET/IMF-0 (5%). A significant difference (p<0.001) was observed between clustering index values in ET and IMF cases. A peculiar proliferative feature of megakaryocytes, defined coupling, was detected in all ET cases. MVD was more pronounced and the number of CD34+ cells higher in cases of IMF than in cases of ET (p <0.005; p = 0.001, respectively) and MVD significantly correlated with the extent of fibrosis (r=0.861). ET cases showed the lowest values of proliferation; IMF-0 and IMF-1 showed higher values while a decrease of MPI was observed in IMF-2 in accordance with the increase of fibrosis. INTERPRETATION AND
CONCLUSIONS: In the diagnosis of thrombocythemic disorders, a multidisciplinary approach must include the evaluation of bone marrow biopsies. Some histopathological criteria, along with the use of markers related to activity and proliferation such as CD34 and MIB-1, underline the biological differences between ET and prefibrotic states of IMF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339673

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  13 in total

Review 1.  Anagrelide: a review of its use in the management of essential thrombocythaemia.

Authors:  Antona J Wagstaff; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool.

Authors:  Zbigniew Rudzki; Rafał Kawa; Krzysztof Okoñ; Ewa Szczygieł; Jerzy Stachura
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

3.  Myelofibrotic transformation in essential thrombocythemia.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

Review 4.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

5.  European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.

Authors:  Thomas Buhr; Konnie Hebeda; Vassiliki Kaloutsi; Anna Porwit; Jon Van der Walt; Hans Kreipe
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

6.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

7.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

8.  Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.

Authors:  Serena Rupoli; Gaia Goteri; Paola Picardi; Giorgia Micucci; Lucia Canafoglia; Anna Rita Scortechini; Irene Federici; Federica Giantomassi; Lidia Da Lio; Antonio Zizzi; Elisa Honorati; Pietro Leoni
Journal:  Diagn Pathol       Date:  2015-04-16       Impact factor: 2.644

9.  Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.

Authors:  Sara Capolla; Chiara Garrovo; Sonia Zorzet; Andrea Lorenzon; Enrico Rampazzo; Ruben Spretz; Gabriele Pozzato; Luis Núñez; Claudio Tripodo; Paolo Macor; Stefania Biffi
Journal:  Int J Nanomedicine       Date:  2015-06-22

Review 10.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.